Topline results were announced from a phase 3 study evaluating sotatercept-csrk in recently diagnosed adults with pulmonary arterial hypertension (PAH).

Topline data were announced from a phase 3 trial evaluating zanzalintinib in combination with atezolizumab in patients with previously treated non-microsatellite instability (MSI)-high metastatic ...

A single dose of a synthetic, proprietary formulation of psilocybin (COMP360) was found to improve symptoms in patients with treatment-resistant ...

HealthDay News — Cannabis use is associated with major adverse cardiovascular events (MACE), according to a systematic review based on real-world data published online June 17 in Heart.

Decision-making was influenced by patient values and did not vary by stage, race and ethnicity, or demographics ...

The Food and Drug Administration (FDA) has approved Harliku ™ (nitisinone) for the reduction of urine homogentisic acid (HGA) in adult patients with alkaptonuria.

The Food and Drug Administration (FDA) has approved Monjuvi ® (tafasitamab-cxix), in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory (R/R) ...

Through August 16, 2024, the Agency has identified 13 cases worldwide of hyperthermia associated with scopolamine patches.

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult patients with bullous pemphigoid.

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Havers presented data showing that infants under 6 months old had the highest rates of COVID-related hospitalizations, The Post reported.